Our library of drug research abstracts drawn from the medical literature is updated on a regular schedule, and you can be assured that new pepcid research articles will be listed here shortly after becoming available to us.
Related Sponsors
Medical research on pepcid
Pak J Biol Sci. 2008 Feb 1; 11(3): 416-21
Morteza Z, Vahhab B, Hossein J
In this study, the effect of intracerebroventricular (i.c.v) injection of H1, H2 and H3 antagonists on feed intake induced by GABA(A) agonist was evaluated. In Experiment 1, the animals received chloropheniramine, a H1 antagonist and then muscimol, a GABA(A) agonist. In Experiment 2, chickens received famotidine, a H2 receptor antagonist, prior to injection of muscimol. Finally in Experiment 3, the birds were injected with thioperamide, a H3 receptor antagonist and muscimol. Cumulative food intake was measured 15, 30, 45, 60, 90, 120, 150 and 180 min after injections. The results of this study indicated that effects of muscimol on food intake inhibited by pretreatment with chloropheneramine maleate (p < or = 0.05), significantly, while the famotidine and thioperamide were ineffective. These results suggest the existence of H1-receptor mediated histamine-GABA(A) receptor interaction on food intake in broiler cockerels.
Am J Health Syst Pharm. 2008 Sep 15; 65(18): 1735-59
Kupie TC, Trusley C, Ben M, Trissel LA
PURPOSE: The physical and chemical compatibility of palonosetron hydrochloride with atropine sulfate, famotidine, heparin sodium, lidocaine hydrochloride, and potassium chloride during simulated Y-site administration were studied. METHODS: Test samples were prepared in duplicate by separately mixing 7.5-mL samples of undiluted palonosetron hydrochloride 50 microg/mL with 7.5-mL samples of atropine sulfate 0.4 mg/mL, famotidine 2 mg/mL, undiluted heparin sodium 100 units/mL, lidocaine hydrochloride 10 mg/mL, and potassium chloride 0.1 meq/mL diluted in 5% dextrose in colorless 15-mL borosilicate glass screw-cap culture tubes with polypropylene caps. Physical stability of the admixtures was assessed by visual examination and by measuring turbidity and particle size and content. Chemical stability of atropine sulfate, famotidine, heparin sodium, and lidocaine hydrochloride was assessed by stability-indicating high-performance liquid chromatography. Potassium chloride concentration was determined by indirect potentiometry using a potassiumion selective electrode. RESULTS: All of the samples of palonosetron hydrochloride with the test drugs were initially clear and colorless in normal fluorescent room light and when viewed with a Tyndall beam. Changes in turbidity for the samples were minor throughout the study. Measured particulates of 10 mum or larger were found to be few in number in all samples and remained so throughout the observation period. The admixtures remained colorless throughout the study. No loss of palonosetron hydrochloride occurred with any of the drugs over four hours. Similarly, little or no loss of the other drugs occurred in four hours. CONCLUSION: Palonosetron hydrochloride is physically and chemically stable with atropine sulfate, famotidine, heparin sodium, lidocaine hydrochloride, and potassium chloride during simulated Y-site administration.
PEGylated PPI dendritic architectures for sustained delivery of H(2) receptor antagonist.
Eur J Med Chem. 2008 Jun 26;
Gajbhiye V, Vijayaraj Kumar P, Tekade RK, Jain NK
The present study was aimed at synthesizing and exploring the use of long circulating biocompatible PEGylated PPI 5.0G dendrimers for sustained delivery of a H(2) receptor antagonist, Famotidine. PPI 5.0G dendrimers were synthesized and PEGylated using dicarboxylic acid PEG 2000. PEGylation was confirmed by SEC, IR, NMR and MASS spectroscopies. Famotidine was loaded in PEGylated dendritic system and confirmed by IR and differential scanning calorimetry. The PEGylated dendritic system has shown an increased drug loading capacity, a reduced hemolytic toxicity and demonstrated a suitability of PEGylated PPI 5.0G dendrimer for prolonged delivery of Famotidine during in vitro release, in vivo blood level and tissue distribution studies in albino rats. The ulcer index after 5h of treatment with different formulations was found to be 4.5+/-0.28 in case of plain Famotidine solution, while ulcer index was significantly reduced to 0.5+/-0.13 in case of Famotidine loaded PEGylated PPI 5.0G dendrimers, indicating sustained release of the drug from drug-PEGylated dendrimer complex. The results suggested that such PEGylated dendrimeric systems could serve as nanoparticulate depot for drugs in body.
Biol Trace Elem Res. 2008 Aug 23;
Koc M, Imik H, Odabasoglu F
Reactive oxygen species (ROS) have been implicated in the etiology of indomethacin-induced gastric mucosal damage. This study investigated ascorbic acid (vitamin C)'s protective effects against oxidative gastric mucosal damage induced by indomethacin. Ascorbic acid is a powerful antioxidant because it can donate a hydrogen atom and form a relatively stable ascorbyl free radical. We have investigated alterations in the levels of myeloperoxidase, antioxidant system enzymes (glutathione S-transferase, superoxide dismutase, glutathione reductase, catalase, glutathione peroxidase), lipid peroxidation and glutathione, as markers for ulceration process following oral administration of ascorbic acid, famotidine, lansoprazole, and ranitidine in rats with indomethacin-induced ulcers. In the present study, we found that (1) ascorbic acid, famotidine, lansoprazole and ranitidine reduced the development of indomethacin-induced gastric damages; (2) the administration of indomethacin caused a significant decrease in the levels of superoxide dismutase, glutathione peroxidase, glutathione S-transferase and glutathione, and an increase in the lipid peroxidation level; (3) the administration of ascorbic acid reversed the trend, inducing a significant increase of these enzymes' levels and a reduction in lipid peroxidation level in tissues; and (4) catalase, glutathione reductase and myeloperoxidase activities, increased by indomethacin, were found to be lower in the ascorbic acid, famotidine, lansoprazole and ranitidine-treated groups. The results indicate that the gastroprotective properties of ascorbic acid could be related to its positive effects on the antioxidant system and myeloperoxidase activity in indomethacin-induced gastric ulcers in rats.
Drug Dev Ind Pharm. 2008 Aug 8; 1-8
Cheng WT, Lin SY, Wang SL
Differential scanning calorimetry (DSC) combined with a curve-fitting program was utilized to quantitatively determine the polymorphic composition of famotidine in the compacts prepared by different compression treatments. Two types of famotidine compacts (compact I or II) were prepared by compressing a conical shape or a flattened shape of powder bed of famotidine form B. The compact I was constructed by a transparent region in the center with an opaque region surrounded outside, but the compact II was formed by a whole opaque region only. A drilled disc sample was prepared and then directly determined by DSC analysis. The Raman spectral results clearly indicate that all the compacts whether in any region before DSC determination were only of famotidine form B and independent of compression pressure applied. Under DSC determination, however, the curve-fitted relative compositions of form B in the drilled disc I sample were gradually reduced to 23-24% with the increase of compression pressure, whereas the curve-fitted relative composition of form A was slowly increased up to 76-77%. A transitional phase of famotidine form B (form B*) in the transparent region of the compact I after applying >150 kg/cm(2) of compression pressure was easily detected, and then transformed to famotidine form A under DSC heating process. But this transitional phase and polymorphic transformation of famotidine could not be detected by other spectroscopic methods. This suggests that the DSC heating system was a preferred method not only to quantitatively analyze the polymorphic transformation of famotidine but also to find a newly transitional phase of famotidine in the compressed compact.
Drug Dev Ind Pharm. 2008 Aug 7; 1-8
Gupta R, Pathak K
The objective of this study was to optimize floating microballoons of famotidine by the emulsion solvent diffusion technique using central composite design. Formulations F(1)-F(15) were prepared using three independent variables (pH of medium, drug: Eudragit(R) S100 ratio and ethanol : dichloromethane ratio) and evaluated for dependent variables (shape, percentage buoyancy, and encapsulation). The optimized formulation F(9) was fractionated and a polymer combination of (Eudragit(R) S100 : Eudragit(R) L100-55, 9.5:0.5) resulted in microballoons that exhibited zero order release (94.73%) with 84.20% buoyancy at the end of the eighth hour when studied in the mesh-designed modified USP type II apparatus.
J Clin Biochem Nutr. 2008 Jul; 43(1): 34-40
Naito Y, Iinuma S, Yagi N, Boku Y, Imamoto E, Takagi T, Handa O, Kokura S, Yoshikawa T
The clinical efficacy of gastroprotective drugs or low-dose H(2) receptor antagonists in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy is limited. The aim of the present study was to investigate efficacy of rebamipide and famotidine in Helicobacter pylori (H. pylori)-negative healthy volunteers taking NSAID. This study was a randomized, two way crossover study comparing the preventive effect rebamipide 100 mg, t.i.d. and famotidine 10 mg, b.i.d against indomethacin (25 mg, t.i.d.)-induced gastric mucosal injury in H. pylori-negative healthy volunteers. 12 subjects satisfied criteria and were randomized. Endoscopy was performed at baseline and again after the treatment for 7 days, and symptoms were recorded during the treatment. Tissue levels of lipid peroxides and myeloperoxidase and serum indomethacin concentrations were also measured. Subjective symptoms were developed in 58% (7/12) of the rebamipide group, and in 75% (9/12) of the famotidine group (no significant differences). The incidence of gastric lesions (modified Lanza score 2 or higher) was 17% (2/12) in the rebamipide group and 25% (3/12) in the famotidine group. Peptic ulcers did not occur in both groups. There were no significant differences in tissue levels of lipid peroxide and myeloperoxidase and serum level of indomethacin between two groups after the treatment. In conclusion, these data recommend rebamipide (100 mg, t.i.d.) or famotidine (10 mg, b.i.d.) for the prevention of acute gastric injury induced by NSAID in patients without a particular risk factor.
J Cardiol. 2008 Aug; 52(1): 39-48
Tanaka S, Nishigaki K, Ojio S, Okubo M, Yasuda S, Ishihara Y, Kubota T, Takasugi N, Kawamura I, Yamaki T, Ushikoshi H, Aoyama T, Kawasaki M, Takemura G, Minatoguchi S
BACKGROUND: Aspirin and anti-platelet drugs are used commonly for patients with coronary heart disease. Proton pump inhibitor (PPI) and high-dose H2-blocker were recommended for preventing NSAIDs-related ulcer. Previously H2-blocker reported to have some negative cardiovascular effects. Additionally, a recent in vitro study showed that PPI reduced cardiac contractility. In this study, we evaluated whether chronic administration of PPI and high-dose H2-blocker affects left ventricular function. METHOD: Fifty-two stable angina patients were enrolled and classified into PPI group ([P]; lansoprazole: 15mg/day, n=28), H2-blocker group ([H]; famotidine: 40mg/day, n=8), and control ([C]; none or mucosal-defense drug, n=16). Eligible patients showed normal cardiac function in initial catheterization without administrated PPI or H2-blocker. They received percutaneous coronary intervention and follow-up catheterization. We compared changes in ejection fraction (EF: %), end diastolic/systolic volume index (EDVI/ESVI: ml/m(2)), and peak positive/negative dp/dt (+/-dp/dt: mmHg/s) in left ventricular angiography series. RESULT: There were no significant differences among three groups regarding patient characteristics, backgrounds of angiographic and intervention, except for fewer smokers in [C]. Other drugs such as beta- and Ca-blocker did not have effects on cardiac function except for aspirin during 255+/-115 days follow-up. Rate of EF changes significantly decreased in [P], and tended to decrease in [H] (C: 3.8+/-9.8%, H: -1.6+/-7.6%, P: -2.1+/-5.9%; p
J Gastroenterol. 2008; 43(6): 448-56
Hongo M, Kinoshita Y, Haruma K
BACKGROUND: To investigate whether histamine H2-receptor antagonists are sufficient to treat heartburn in nonerosive reflux disease in Japanese, who produce less gastric acid than Westerners, the efficacy of famotidine in Japanese nonerosive reflux disease patients was studied in a double-blind, placebo-controlled, parallel group-comparative, multicenter study. METHODS: The Los Angeles classification system with Japanese modifications was used to assess the severity of nonerosive reflux disease. Famotidine (10-or 20-mg doses) or placebo was administered to patients twice daily for 8 weeks. Heartburn symptoms were recorded daily by patients. RESULTS: A total of 528 patients participated in the study. The percentage of days without heartburn, the primary end point of the efficacy evaluation, was 62% for 40 mg and 59% for 20 mg of famotidine, and 55% for placebo, with a statistically significant difference between the 40-mg dose and placebo (P = 0.001; significance level, 0.025 one-sided). Famotidine at both doses provided immediate relief from heartburn, and relief persisted throughout the 8-week study with the 40-mg dose. CONCLUSIONS: The results indicate that famotidine relieves heartburn symptoms in Japanese nonerosive reflux disease patients.
Famotidine versus pantoprazole.
Am J Crit Care. 2008 Jul; 17(4): 311-2; author reply 312
Lwin AA